Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of modified Buyang huanwu decoction on hemorheology, myocardial remodeling, serum soluble CD40 ligand and serum soluble P-selectin in patients with acute myocardial infarction after percutaneous coronary intervention

Juanxia Li¹, Fanhua Meng¹, Xiaoxu Li², Xingrui Zheng³, Hua Shi⁴, Xiaolong Li⁵ , Haijun Zhao⁵

¹Second Department of Geriatrics, Zhangjiakou First Hospital, Zhangjiakou 075000, China; ²Department of Surgical Anesthesia, Zhangjiakou First Hospital, Zhangjiakou 075000, China; ³Yuershan Community Health Service Station, Zhangjiakou First Hospital, Zhangjiakou 075000, China; ⁴Department of Chinese Medicine, Zhangjiakou First Hospital, Zhangjiakou 075000, China; ⁵Department of Breast Surgery, Shijiazhuang Fourth Hospital, Shijiazhuang 050000, Hebei Province, China.

For correspondence:- Xiaolong Li Email: mazeluo28522573130@163.com

Accepted: 2 February 2024 Published: 29 February 2024

Citation: Li J, Meng F, Li X, Zheng X, Shi H, Li X, et al. Effect of modified Buyang huanwu decoction on hemorheology, myocardial remodeling, serum soluble CD40 ligand and serum soluble P-selectin in patients with acute myocardial infarction after percutaneous coronary intervention. Trop J Pharm Res 2024; 23(2):371-378 doi: 10.4314/tjpr.v23i2.17

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of modified Buyang Huanwu decoction on hemorheology and myocardial remodeling in patients with acute myocardial infarction (AMI) after conventional percutaneous coronary intervention (PCI), and its relationship with serum levels of soluble CD40 ligand (sCD40L) and soluble P-selectin (sP-sel).

Methods: After PCI, 80 patients seen from February 2021 to February 2022 in Shijiazhuang Fourth Hospital, China with AMI were enrolled in the study. Subjects were assigned to study and control groups. Control group received standard conventional medical treatments, while study group received modified Buyang Huanwu decoction, in addition to the same standard treatment, orally twice a day (morning and night) for 3 months). The effect of modified Buyang Huanwu decoction was determined by comparing the post-treatment clinical outcomes and levels of hemorheology indices and myocardial remodeling-associated indices (myocardial injury markers) in both groups of patients.

Results: The clinical outcome in study group was significantly better, and the hemorheology indices were significantly improved when compared to control subjects (p < 0.05). Serum levels of myocardial injury markers (cardiac troponin (cTnI), cardiac markers (CRP), and brain natriuretic peptide (BNP)), and inflammatory markers (sCD40L and sP-sel) in study group were significantly decreased to varying degrees, relative to control group (p < 0.05).

Conclusion: Modified Buyang Huanwu decoction reduces inflammatory marker levels, cardiac inflammatory response and myocardial remodeling, and improves the prognosis of AMI in patients after PCI. Therefore, it may be beneficial to develop other methods for treating acute myocardial infarction after percutaneous coronary intervention.

Keywords: Modified Buyang Huanwu decoction, Acute myocardial infarction, percutaneous coronary intervention